Risks factors for death among COVID-19 patients combined with hypertension, coronary heart disease or diabetes

  • Hang YANG ,
  • Lin-cheng YANG ,
  • Rui-tao ZHANG ,
  • Yun-peng LING ,
  • Qing-gang GE
Expand
  • 1. Department of Cardiac Surgery
    2. Department of Cardiology
    3. Department of Intensive Care Unit, Peking University Third Hospital, Beijing 100191, China

Received date: 2020-04-13

  Online published: 2020-06-30

Abstract

Objective: The pathogenesis of myocardial injury upon corona virus disease 2019 (COVID-19) infection remain unknown,evidence of impact on outcome is insufficient, therefore, we aim to investigate the risk factors for death among COVID-19 patients combined with hypertension, coronary heart disease or diabetes in this study.Methods: This was a single-centered, retrospective, observational study. Patients of Sino-French Eco-City section of Tongji Hospital, Wuhan, China attended by Peking University Supporting Medical Team and admitted from Jan. 29, 2020 to Mar. 20, 2020 were included. The positive nucleic acid of COVID-19 virus and combination with hypertension, coronary heart disease or diabetes were in the standard. We collected the clinical data and laboratory examination results of the eligible patients to evaluate the related factors of death.Results: In the study, 94 COVID-19 patients enrolled were divided into the group of death (13 cases) and the group of survivors (81 cases), the average age was 66.7 years. Compared with the survival group, the death group had faster basal heart rate(103.2 beats/min vs. 88.4 beats /min, P=0.004), shortness of breath(29.0 beats /min vs. 20.0 beats /min, P<0.001), higher neutrophil count(9.2×109/L vs. 3.8×109/L, P<0.001), lower lymphocyte count(0.5×109/L vs. 1.1×109/L, P<0.001), creatine kinase MB(CK-MB, 3.2 μg/L vs. 0.8 μg/L, P<0.001), high sensitivity cardiac troponin Ⅰ(hs-cTnⅠ, 217.2 ng/L vs. 4.9 ng/L, P<0.001), N-terminal pro brain natriuretic peptide(NT-proBNP; 945.0 μg/L vs. 154.0 μg/L, P<0.001), inflammatory factor ferritin(770.2 μg/L vs. 622.8 μg/L , P=0.050), interleukin-2 recepter(IL-2R, 1 586.0 U/mL vs. 694.0 U/mL, P<0.001), interleukin-6(IL-6, 82.3 ng/L vs. 13.0 ng/L, P<0.001), interleukin-10(IL-10, 9.8 ng/L vs. 5.0 ng/L, P<0.001)were higher than those in the survival group. Univariate logistic regression analysis showed that the risk factors for death were old age, low non oxygen saturation, low lymphocyte count, myocardial injury, abnormal increase of IL 2R, IL-6, and IL-10. Multivariate regression showed that old age (OR=1.11, 95%CI=1.03-1.19, P=0.026), low non oxygen saturation(OR=0.85, 95%CI=0.72-0.99, P=0.041), and abnormal increase of IL-10(>9.1 ng/L, OR=101.93, 95%CI=4.74-2190.71, P=0.003)were independent risk factors for COVID-19 patients combined with hypertension, coronary heart disease or diabetes.Conclusion: In COVID-19 patients combined with hypertension, coronary heart disease or diabetes, the risk factors for death were old age, low non oxygen saturation, low lymphocyte count, myocardial injury, and abnormal increase of IL-2R, IL-6, and IL-10. Old age, low non oxygen saturation and abnormal increase of IL-10 were independent risk factors.

Cite this article

Hang YANG , Lin-cheng YANG , Rui-tao ZHANG , Yun-peng LING , Qing-gang GE . Risks factors for death among COVID-19 patients combined with hypertension, coronary heart disease or diabetes[J]. Journal of Peking University(Health Sciences), 2020 , 52(3) : 420 -424 . DOI: 10.19723/j.issn.1671-167X.2020.03.004

References

[1] Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J]. Sci China Life Sci, 2020,63(3):457-460.
[2] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020,395(10223):497-506.
[3] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[J]. Lancet, 2020,395(10229):1054-1062.
[4] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 2(2020-02-07)[2020-04-06]. https://jamanetwork.com/journals/jama/fullarticle/2761044.
[5] Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018)[J]. J Am Coll Cardiol, 2018,72(18):2231-2264.
[6] Chan JWM, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)[J]. Thorax, 2003,58(8):686-689.
[7] Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area[J]. JAMA, 2003,289(21):2801-2809.
[8] Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis[J]. Int J Infect Dis, 2016,49:129-133.
[9] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020,181(2):271-280.
[10] Hamming I, Timens W, Bulthuis M, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis[J]. J Pathol, 2004,203(2):631-637.
[11] Keidar S, Kaplan M, Gamliellazarovich A, et al. ACE2 of the heart: From angiotensin Ⅰ to angiotensin (1-7)[J]. Cardiovasc Res, 2007,73(3):463-469
[12] Clerkin KJ, Fried JA, Raikhelkar J, et al. Corona virus disease 2019 (COVID-19) and cardiovascular disease[J]. Circulation, 2020, 3(2020-03-21)[2020-04-07]. https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.120.046941.
[13] Guan W, Ni Z, Hu Y, et al. Clinical characteristics of corona virus disease 2019 in China[J]. N Engl J Med, 2020,382(18):1708-1720.
[14] Hu H, Ma F, Wei X, et al. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin[J]. Eur Heart J, 2020, (2020-03-16)[2020-04-08]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184348.
[15] Sala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection[J] Eur Heart J, 2020, 4(2020-04-08)[2020-04-10]. https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa286/5817735.
[16] Chen Z, Hu Y, Xiong T, et al. IL-10 promotes development of acute respiratory distress syndrome via inhibiting differentiation of bone marrow stem cells to alveolar type 2 epithelial cells[J]. Eur Rev Med Pharmacol Sci, 2018,22:6085-6092.
[17] Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology[J]. Semin Immunopathol, 2017,39(5):529-539.
[18] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020,395(10223):507-513.
[19] Watts ER, Walmsley SR. Inflammation and Hypoxia: HIF and PHD Isoform Selectivity[J]. Trends Mol Med, 2019,25(1):33-46.
[20] Campbell EL, Bruyninckx WJ, Kelly CJ, et al. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation[J]. Immunity, 2014,40(1):66-77.
Outlines

/